Momelotinib
Details of the Drug
- Generic Name:
- Momelotinib
- Drug Type:
- Janus kinase (JAK) inhibitor
- How the Drug is Given:
By mouth
- Names:
- Momelotinib
- Ojjaara
Indications and Usage
Momelotinib is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
Side effects needing medical attention
The most common adverse reactions are thrombocytopenia, hemorrhage, bacterial infection, fatigue, dizziness, diarrhea, and nausea.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.